-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
WHO WE HELP
-
Pharmaceutical Manufacturers
-
Emerging Biopharma
-
MedTech
-
Financial Institutions
-
Government and Public Health
-
Health Plans
-
Hospital and Health Systems
-
Insurers and Risk
-
Medical Specialty and Patient Advocacy
Pharmaceutical Manufacturers
Harness unparalleled healthcare data, advanced analytics, and cutting-edge technologies with our expertise to accelerate the development and commercialization of innovative medicines, enhancing patient lives.
Discover MorePharmaceutical Manufacturers
Emerging Biopharma (Global page)
Boost your innovation with IQVIA's expert team. Our comprehensive solutions integrate top-tier insights, technology, and expertise to maximize your asset's success in a competitive landscape.
Discover InnovationsMedTech
Navigating MedTech's unique landscape: U.S. decision-making now rests with GPOs, IDNs, and payers, who demand solid value proof through rigorous outcomes analyses and pricing scrutiny.
Explore MedTechMedTech
Financial Institutions
Invest in healthcare with confidence. Stay ahead of pharma and medical device trends using real-time, high-quality data. Access market insights, historical sales, prescription trends, and emerging product information for informed, risk-reduced decisions.
Access InsightsGovernment and Public Health
Unlock deeper health insights with unmatched data and innovative technology to enhance decision-making for your essential government programs.
Unlock InnovationsGovernment and Public Health
Health Plans
Accelerate digital innovation with our data-driven expertise in data science and healthcare, optimizing business processes for smarter decisions.
Navigate Health PlansHospital and Health Systems
Leverage digital innovation to cut costs, boost efficiency, and elevate patient engagement, all while enhancing quality and health outcomes.
Streamline DecisionsHospital and Health Systems
Insurers and Risk
Enhance your ability to evaluate and forecast population risk swiftly and accurately by integrating unmatched data, expertise, and technology.
Uncover More
Medical Specialty and Patient Advocacy
Transform into a data-driven organization that enhances your specialty and showcases value to your members through digital transformation.
Explore NowU.S. PROGRESS POINT
A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREBLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTS
PODCASTS
"Discover the future through our enlightening podcasts available in the United States.
EXPLORE PODCASTS
Blog
4 Pillars of a DEA Compliance Program
Nov 12, 2020
COVID-19 has created a lot of uncertainty for manufactures and distributors of controlled substances.
The chaos caused by the pandemic, coupled with rising opioid addiction rates in the United States, has led to unprecedented times in this industry, and made it clear that having a robust compliance program and strong product stewardship is vital to protecting lives and the business model.
The key to creating an effective compliance program is to use DEA rules as a framework, and meeting all of the requirements for registration, record-keeping, reporting, and security.
Compliance Basics
Regardless of the environment in which a drug is being distributed, a compliant program must adhere to the Controlled Substances Act (CSA). The CSA provides the Drug Enforcement Administration (DEA) with the authority to regulate handling of all controlled substances, including registration, record-keeping, reporting, and security. Failure to adhere to any one of these mechanisms can result in the loss of DEA registration and significant civil fines.
Registration: If you want to legally handle controlled substances, you have to be registered with DEA in the state or jurisdiction where you are based. You also need to have a separate registration for every location where the controlled substances will be stored for distribution to the public.
Record-keeping: Every registrant is required to maintain complete, accurate, and up-to-date records for any controlled substance they manufacture, import, receive, sell, deliver, export, or otherwise dispose of. The record-keeping must include details about every handling step, documenting how the product is created, moved, and sold. This is an area where a lot of inadvertent violations can occur due to incomplete and inaccurate record-keeping.
Reporting: Registrants can now use the Automation of Reports and Consolidated Orders System (ARCOS) system to submit reports related to all thefts, significant loss, and suspicious orders. ARCOS is an automated drug reporting system that monitors the flow of controlled substances from manufacture, through sale and distribution. Registrants can use ARCOS to transmit required monthly or quarterly reports, rather than mailing them, which adds speed and cost savings to the process.
ARCOS accumulates these transactions which are then summarized into reports that can be used to identify the diversion of controlled substances into illicit channels of distribution. It also allows DEA to look at what’s moving through the chain of distribution.
If you experience theft or significant loss, you must report it to the DEA within one business day of discovery via the DEA 106 form. In these situations, record-keeping is key to support and prove an adequate investigation.
Security: The DEA also requires all applicants and registrants provide effective security controls to guard against theft and diversion of controlled substances.
An effective security program includes physical controls – cameras and alarms, locked gates and doors, limited access to storage facilities, and formal monitoring of vehicles entering the plan area.
Operators should also have formal process in place for monitoring the ordering system to identify suspicious orders, and for conducting due diligence on all members in their supply chain – from suppliers to customers. This due diligence review should be updated regularly with all data documented for review.
Maintaining DEA compliance requires a lot of effort and paperwork, but if you make these four pillars the foundation for your controlled substance compliance program, you will have the tools in place to ensure compliance and survive your next inspection.
DEA Compliance for Manufacturers and Distributors in Today’s Virtual Times
Learn more about building a strong foundation for your controlled substance compliance program by viewing this webinar on demand.